TOKYO (Reuters) – Japanese biopharmaceutical firm Anges Inc said on Tuesday it and partner Osaka University had completed development of a prophylactic DNA vaccine against the new coronavirus and that it would begin testing it in animals soon.
Shares of Anges were untraded with a glut of buy orders in early morning.
There are now more than 350,000 cases of coronavirus infections globally and over 15,000 deaths resulting from the disease it causes, called COVID-19.
Reporting by Chang-Ran Kim; Editing by Kim Coghill
Our Standards:The Thomson Reuters Trust Principles.
This article was originally published by Reuters.com. Read the original article here.
English 
Azerbaijani